摘要
Abstract
Objective:To investigate the clinical study of modified Liujunzi Decoction combined with Ohitinib Tablets in the treatment of advanced spleen-deficiency phlegm-dampness type non-small cell lung cancer.Method:A total of 74 patients with advanced spleen deficiency and phlegm-dampness non-small cell lung cancer admitted to Taishan Hospital of Traditional Chinese Medicine from June 2022 to June 2023 were selected,they were divided into two groups by random number table method,with 37 cases in each group.The control group was treated with Ocitinib Tablets,and the study group was treated with modified Liujunzi Decoction combined with Ocitinib Tablets.The therapeutic effect,quality of life,adverse reactions,immune function and angiogenesis factor levels of the two groups were compared.Result:The total effective rate of the study group(72.97%)was higher than that of the control group(45.95%),the difference was statistically significant(P<0.05).After treatment,the quality of life such as material function,social function,daily life and psychological function in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group(10.81%)was lower than that in the control group(37.84%),the difference was statistically significant(P<0.05).After treatment,the immune functions of natural killer cells(NK),CD4+,CD8+and CD3+in the study group were better than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of hypoxia-inducing factor 1α(HIF-1α)and vascular endothelial growth factor(VEGF)in the study group were better than those in the control group,the differences were statistically significant(P<0.05).Conclusion:The treatment effect of modified Liujunzi Decoction combined with Ohetinib Tablet is ideal for patients with advanced non-small cell lung cancer with spleen-deficiency and phlegm-dampness,which can effectively improve the immune function and the overall level of angiogenesis factors,reduce the overall incidence of adverse reactions,and improve the clinical quality of life.关键词
六君子汤加减/奥希替尼片/联合治疗/晚期脾虚痰湿型/非小细胞肺癌Key words
Modified Liujunzi Decoction/Ocitinib tablets/Combination therapy/Advanced spleen deficiency phlegm-dampness type/Non-small cell lung cancer
